Delpharm expands its pharmaceutical development services with the acquisition of Dr Reddy's Leiden development center in the Netherlands

In October 2012, Dr. Reddy's Laboratories, acquired Netherlands-based Octopus for €27.4 million as part of its plan to expand its research and development (R&D) base. The offering price was 30% above OctoPlus' market capitalization in October 2012. OctoPlus will become Dr. Reddy's center of excellence for complex injectables. OctoPlus' total revenue for the first six months of calendar year 2012 was €4.8 million, with a net loss of €5.8 million.

In 2017, Dr. Reddy's Laboratories Ltd. renamed its Dutch research center Octoplus, and affiliated legal entities of OctoPlus, to Dr. Reddy's Research and Development B.V.

OctoPlus has become a fully integrated center of excellence for the development of Dr. Reddy's complex injectables. Dr. Reddy's R&D, located in Bio Science Park Leiden, is one of two R&D centers based in Europe. In 2017, the center had a staff of over 100 employees.

At the end of December 2022, Dr Reddy Laboratories said its subsidiary DRRDBV had entered into an agreement to sell certain assets and liabilities of its Netherlands-based site. Dr Reddy's Research and Development B V (DRRDBV), a subsidiary of Hyderabad-based Dr Reddy, has entered into an asset purchase agreement with Delpharm Development Leiden BV, part of the French Delpharm Group.

The assets acquired by Delpharm consist of a 3,500 square meter site created in 1995, with 40 highly qualified people. The site is equipped with technologies to develop injectable formulations for chemical molecules and biological products and to manufacture batches for clinical trials.

With the acquisition of the Leiden site, Delpharm is now positioned as a complete player in injectables, ranging from formulation, analytical development, batch manufacturing phase 1 clinical trials, through regulatory affairs, up to production in one of the group's four industrial production sites for injectables (3 in France and 1 in Canada).